Clinical Trial Detail

NCT ID NCT03412773
Title Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors BeiGene
Indications

hepatocellular carcinoma

Therapies

Tislelizumab

Sorafenib

Age Groups: adult senior

No variant requirements are available.